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N UMEROUS recent studies have suggested that induc-
tion of donor-specific tolerance (OST) is an active 
process that requires the engagement of donor antigen-
presenting cells with the recipient's alloreactive T cells. l 
Under appropriate conditions, this interaction results in 
antigen-dependent. activation-induced apoptosis of reactive 
T cells with their eventual deletion. Thus, the basic premise 
of this argument is that immune activation is a required 
event in the progressive induction of OST and that episodes 
of acute cellular rejection (ACR) are essentially a corollary 
of this process. Since 1992, our center has been involved in 
a clinical trial mandating adjuvant donor bone marrow 
(EM) infusion to induce DST in orthotopic liver transplant 
(OLT) recipients. 2 This study was designed to ascertain the 
incidence and the severity of ACR in EM-augmented and 
control OLT recipients and to correlate these findings with 
patient and graft survival in these two cohorts. 
PATIENTS AND METHODS 
Since the initiation of this study, 77 adult unconditioned primary 
OLT recipients have received a single or mUltiple perioperative 
infusions of unmodified donor BM cells (3 to 6 x lO"/kg). In 
addition, for purposes of this analysis, patients who consented (n = 
50) and those receiving primary OLT prior to and immediately 
after the accrued study subjects (n = 154) without BM infusion 
served as controls. Donor gender and age were additional param-
eters that were used to match the "artificial" controls to patients in 
the study cohort. The number of patients with evidence of biopsy-
proven rejection as well as the total number of rejection episodes 
were analyzed'. To estimate the occurrence of biopsy-proven rejec-
tion, person-time analysis with ACR incidence rate (IR) and 
incidence rate ratio (IRR) was employed; an approximate Poisson 
method was used to build a 95% confidence interval (CI) for IRR 
analysis. A one-way analysis of variance (ANOVA) model was used 
to compare the IR means estimated at various timepoints post-
transplantation between groups. For determination of time be-
tween transplantation and the first episode of ACR, the product-
limit estimator was used. P < .05 or, alternatively, the 95% cr, 
which did not include unity within the bounds, were considered 
statistically significant. 
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RESULTS AND DISCUSSION 
No significant difference (P > .56) was observed in the IR 
in patients in the study (.239) and the two control (.206) 
cohorts during the course of their follow-up; the time to 
first ACR was also comparable. Compared with controls. 
the IRR with the 95% CI in study patients was 1.16 (0.83, 
1.82J. There was, however, a tendency for a slightly higher 
incidence of rejection in 8M-augmented patients during the 
first 24 months posttransplantation-a trend that reversed 
during the subsequent period of follow-up. At 6 years 
posttransplantation, patient and graft survival was 81 % and 
74%, and 77% and 70% in the control patients, respec-
tively. 
Taken together these data suggest that, despite a slightly 
higher incidence of ACR in 8M-infused liver recipients 
during the first 2 years post-Tx, patient and graft survivals 
were superior in the study patients as compared with 
controls. These findings are similar to those in rodents 
suggesting that "active" Ag presentation may be a more 
robust mechanism for eventual donor-specific immune 
modulation. 
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